» Articles » PMID: 3894793

Recurrent Diabetes Mellitus in the Pancreas Iso- and Allograft. A Light and Electron Microscopic and Immunohistochemical Analysis of Four Cases

Overview
Journal Lab Invest
Specialty Pathology
Date 1985 Aug 1
PMID 3894793
Citations 103
Authors
Affiliations
Soon will be listed here.
Abstract

Four patients with type 1 diabetes mellitus received segmental pancreatic grafts. The donors were HLA-identical twins in three patients and an HLA-identical sibling in one. Each patient had normal glucose metabolism in the posttransplantation period but impaired graft function developed after 6 to 12 weeks. Complete loss of function developed in three patients. The fourth patient received immunosuppressive therapy but continues to require a low dose of insulin 15 months following transplantation. Pancreatic graft biopsy at the time of declining graft function in three patients revealed a mononuclear cell infiltrate centered upon islets consisting of variable numbers of T11 (pan T), OKT8 (suppressor-killer), OKT9 (transferrin receptor), OKT10 (activated), and HLA-DR-reactive mononuclear cells, as well as 63D3 and OKM1 reactive monocytes. Biopsies obtained following loss of graft function revealed resolution of the inflammatory process and selective destruction of all islet beta-cells in two patients, whereas graft biopsy in one patient demonstrated a mononuclear cell infiltrate in islets containing demonstrable beta-cells but no infiltrate in islets without beta-cells. Following immunosuppressive therapy the fourth patient showed resolution of the insulitis and destruction of beta-cells in 70% of the islets. The variable numbers of beta-cells observed in the remaining islets likely account for the relatively low amount of exogenous insulin required by this patient. There was no immunohistologic evidence of humoral mediated immune reaction in any of the biopsies. It is postulated that selective beta-cell destruction was a consequence of cell-mediated immunity leading to recurrent diabetes mellitus.

Citing Articles

Lymph nodes as gatekeepers of autoimmune diseases.

OByrne A, van Baarsen L RMD Open. 2024; 10(4.

PMID: 39658052 PMC: 11647372. DOI: 10.1136/rmdopen-2024-004097.


Cutting edge of immune response and immunosuppressants in allogeneic and xenogeneic islet transplantation.

Yue L, Li J, Yao M, Song S, Zhang X, Wang Y Front Immunol. 2024; 15:1455691.

PMID: 39346923 PMC: 11427288. DOI: 10.3389/fimmu.2024.1455691.


Genetic Engineering of Immune Evasive Stem Cell-Derived Islets.

Sackett S, Kaplan S, Mitchell S, Brown M, Burrack A, Grey S Transpl Int. 2022; 35:10817.

PMID: 36545154 PMC: 9762357. DOI: 10.3389/ti.2022.10817.


The Influence of Microenvironment on Survival of Intraportal Transplanted Islets.

Yan L, Ye L, Chen Y, He S, Zhang C, Mao X Front Immunol. 2022; 13:849580.

PMID: 35418988 PMC: 8995531. DOI: 10.3389/fimmu.2022.849580.


Alpha-Lipoic Acid Inhibits Spontaneous Diabetes and Autoimmune Recurrence in Non-Obese Diabetic Mice by Enhancing Differentiation of Regulatory T Cells and Showed Potential for Use in Cell Therapies for the Treatment of Type 1 Diabetes.

Huang S, Kuo S, Chen S, Lin J, Chen Y, Hong Z Int J Mol Sci. 2022; 23(3).

PMID: 35163121 PMC: 8835933. DOI: 10.3390/ijms23031169.